The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have newly diagnosed advanced-stage ovarian, fallopian tube or primary peritoneal cancer scheduled to receive neoadjuvant chemotherapy. The purpose of this study is to evaluate the feasibility of receiving chemotherapy with Carboplatin and the investigational drug called Mirvetuximab soravtansine as first-line treatment in subjects that are Folate receptor positive. Surgery will be planned after 4 cycles of neoadjuvant treatment and maintenance treatment will be at discretion of treatment provider.
If you choose to be in this study, your part in the study is expected to last up to 2 years.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04606914